{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:09:19Z","timestamp":1780546159876,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jsat.2021.108661","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:06:40Z","timestamp":1636848400000},"page":"108661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine"],"prefix":"10.1016","volume":"136","author":[{"given":"Michael D.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donnell","family":"VanNoppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra S.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108661_bb0005","author":"Ahmad"},{"key":"10.1016\/j.jsat.2021.108661_bb0010","series-title":"The CBHSQ Report","first-page":"1","article-title":"Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update)","author":"Alderks","year":"2013"},{"issue":"3","key":"10.1016\/j.jsat.2021.108661_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: The foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"41","key":"10.1016\/j.jsat.2021.108661_bb0020","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.15585\/mmwr.mm6541a5","article-title":"Notes from the field: Pediatric emergency department visits for buprenorphine\/naloxone ingestion - United States, 2008\u20132015","volume":"65","author":"Budnitz","year":"2016","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2021.108661_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jsat.2017.10.010","article-title":"Understanding abuse of buprenorphine\/naloxone film versus tablet products using data from ASI-MV(R) substance use disorder treatment centers and RADARS(R) system poison centers","volume":"84","author":"Butler","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108661_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","article-title":"Factors contributing to the rise of buprenorphine misuse: 2008\u20132013","volume":"142","author":"Cicero","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108661_bb0035","unstructured":"Department Of Justice Drug Enforcement Administration (DEA), n.d.Department Of Justice Drug Enforcement Administration (DEA) Diversion Control Division. ARCOS Retail Drug Summary Reports. U.S. Department of Justice. https:\/\/www.deadiversion.usdoj.gov\/arcos\/retail_drug_summary\/ Accessed 6\/18\/21."},{"issue":"1\u20132","key":"10.1016\/j.jsat.2021.108661_bb0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2021.108661_bb0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ADM.0000000000000057","article-title":"Factors affecting noncompliance with buprenorphine maintenance treatment","volume":"8","author":"Fareed","year":"2014","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2021.108661_bb0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1521-0391.2013.12074.x","article-title":"Predictive factors for relapse in patients on buprenorphine maintenance","volume":"23","author":"Ferri","year":"2014","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.jsat.2021.108661_bb0055","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/10550490701860971","article-title":"Long-term treatment with buprenorphine\/naloxone in primary care: Results at 2\u20135 years","volume":"17","author":"Fiellin","year":"2008","journal-title":"The American Journal on Addictions"},{"issue":"1","key":"10.1016\/j.jsat.2021.108661_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","article-title":"Buprenorphine duration of action: Mu-opioid receptor availability and pharmacokinetic and behavioral indices","volume":"61","author":"Greenwald","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jsat.2021.108661_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108447","article-title":"Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse","volume":"131","author":"Greiner","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2021.108661_bb0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/00952990.2013.842241","article-title":"Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder","volume":"40","author":"Griffin","year":"2014","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2021.108661_bb0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: patients' reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10173","key":"10.1016\/j.jsat.2021.108661_bb0080","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jsat.2021.108661_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108661_bb0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2021.108661_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"Journal of Addiction Medicine"},{"issue":"6","key":"10.1016\/j.jsat.2021.108661_bb0100","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108661_bb0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108661_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12888-015-0415-z","article-title":"Buprenorphine maintenance program with contracted work\/education and low tolerance for non-prescribed drug use: A cohort study of outcome for women and men after seven years","volume":"15","author":"Ohlin","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"8","key":"10.1016\/j.jsat.2021.108661_bb0115","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ajad.12292","article-title":"The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders","volume":"24","author":"Saunders","year":"2015","journal-title":"The American Journal on Addictions"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108661_bb0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drugalcdep.2012.06.020","article-title":"Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine\/naloxone treatment","volume":"127","author":"Savant","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"5152","key":"10.1016\/j.jsat.2021.108661_bb0125","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths - United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2018","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1016\/j.jsat.2021.108661_bb0130","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1097\/ADM.0000000000000630","article-title":"Secondary analysis of pain outcomes in a large pragmatic randomized trial of buprenorphine\/naloxone versus methadone for opioid use disorder","volume":"14","author":"Shulman","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"11","key":"10.1016\/j.jsat.2021.108661_bb0135","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"Journal of General Internal Medicine"},{"issue":"7","key":"10.1016\/j.jsat.2021.108661_bb0140","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s11606-015-3212-y","article-title":"Chronic pain and depression among primary care patients treated with buprenorphine","volume":"30","author":"Stein","year":"2015","journal-title":"Journal of General Internal Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2021.108661_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"issue":"4","key":"10.1016\/j.jsat.2021.108661_bb0150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","article-title":"Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients","volume":"46","author":"Tkacz","year":"2014","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:25Z","timestamp":1760039785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221003871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"alternative-id":["S0740547221003871"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108661","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108661"}}